Atea Pharmaceuticals, Inc. Defined Contribution Plan, Cost
Atea Pharmaceuticals, Inc. (AVIR) reported Defined Contribution Plan, Cost of $228.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. defined contribution plan, cost for the quarter ending 2026-06-30 was $228.00K, a 65.22% increase year-over-year.
- Atea Pharmaceuticals, Inc. defined contribution plan, cost for the quarter ending 2026-03-31 was $328.00K, a 3.47% increase year-over-year.
- Atea Pharmaceuticals, Inc. defined contribution plan, cost for the quarter ending 2025-12-31 was $44.00K, a 42.86% decline year-over-year.
- Atea Pharmaceuticals, Inc. defined contribution plan, cost for the quarter ending 2025-09-30 was $75.00K, a 49.66% decline year-over-year.
- Atea Pharmaceuticals, Inc. defined contribution plan, cost for fiscal 2025 was $574.00K, a 27.16% decline from fiscal 2024.
- Atea Pharmaceuticals, Inc. defined contribution plan, cost for fiscal 2024 was $788.00K, a 11.30% increase from fiscal 2023.
- Atea Pharmaceuticals, Inc. defined contribution plan, cost for fiscal 2023 was $708.00K, a 30.87% increase from fiscal 2022.
- Atea Pharmaceuticals, Inc. defined contribution plan, cost for fiscal 2022 was $541.00K, a 98.90% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $228.00K 10-Q · filed 2026-08-12 | $556.00K 10-Q · filed 2026-08-12 | $600.00K derived: sum of 3 quarters · filed 2026-08-12 | $675.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $328.00K 10-Q · filed 2026-05-12 | $372.00K derived: sum of 2 quarters · filed 2026-05-12 | $447.00K derived: sum of 3 quarters · filed 2026-05-12 | $585.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $119.00K derived: sum of 2 quarters · filed 2026-03-05 | $257.00K derived: sum of 3 quarters · filed 2026-08-12 | $574.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $75.00K 10-Q · filed 2025-11-12 | $213.00K derived: sum of 2 quarters · filed 2026-08-12 | $530.00K 10-Q · filed 2025-11-12 | $607.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $138.00K 10-Q · filed 2026-08-12 | $455.00K 10-Q · filed 2026-08-12 | $532.00K derived: sum of 3 quarters · filed 2026-08-12 | $681.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $317.00K 10-Q · filed 2026-05-12 | $394.00K derived: sum of 2 quarters · filed 2026-05-12 | $543.00K derived: sum of 3 quarters · filed 2026-05-12 | $704.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $226.00K derived: sum of 2 quarters · filed 2026-03-05 | $387.00K derived: sum of 3 quarters · filed 2026-03-05 | $788.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $149.00K 10-Q · filed 2025-11-12 | $310.00K derived: sum of 2 quarters · filed 2025-11-12 | $711.00K 10-Q · filed 2025-11-12 | $777.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $161.00K 10-Q · filed 2025-08-07 | $562.00K 10-Q · filed 2025-08-07 | $628.00K derived: sum of 3 quarters · filed 2025-08-07 | $733.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $401.00K 10-Q · filed 2025-05-12 | $467.00K derived: sum of 2 quarters · filed 2025-05-12 | $572.00K derived: sum of 3 quarters · filed 2025-05-12 | $715.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $171.00K derived: sum of 2 quarters · filed 2025-03-06 | $314.00K derived: sum of 3 quarters · filed 2025-03-06 | $708.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $105.00K 10-Q · filed 2024-11-07 | $248.00K derived: sum of 2 quarters · filed 2024-11-07 | $642.00K 10-Q · filed 2024-11-07 | $720.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $143.00K 10-Q · filed 2024-08-07 | $537.00K 10-Q · filed 2024-08-07 | $615.00K derived: sum of 3 quarters · filed 2024-08-07 | $712.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $394.00K 10-Q · filed 2024-05-14 | $472.00K derived: sum of 2 quarters · filed 2024-05-14 | $569.00K derived: sum of 3 quarters · filed 2024-05-14 | $695.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $175.00K derived: sum of 2 quarters · filed 2024-02-28 | $301.00K derived: sum of 3 quarters · filed 2024-02-28 | $541.00K 10-K · filed 2024-02-28 |
| 2022-09-30 | $97.00K 10-Q · filed 2023-11-08 | $223.00K derived: sum of 2 quarters · filed 2023-11-08 | $463.00K 10-Q · filed 2023-11-08 | $557.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $126.00K 10-Q · filed 2023-08-08 | $366.00K 10-Q · filed 2023-08-08 | $460.00K derived: sum of 3 quarters · filed 2023-08-08 | $562.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $240.00K 10-Q · filed 2023-05-08 | $334.00K derived: sum of 2 quarters · filed 2023-05-08 | $436.00K derived: sum of 3 quarters · filed 2023-05-08 | $512.00K derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $196.00K derived: sum of 2 quarters · filed 2023-02-28 | $272.00K derived: sum of 3 quarters · filed 2023-02-28 | $272.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $102.00K 10-Q · filed 2022-11-07 | $178.00K derived: sum of 2 quarters · filed 2022-11-07 | $178.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $76.00K 10-Q · filed 2022-08-08 | $76.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |